Health Care & Life Sciences » Biotechnology | TapImmune Inc.

TapImmune Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
48.60
141.90
6,576.60
7,851.20
5,129.30
Other Current Assets
15.00
82.50
68.80
70.10
51.20
Total Current Assets
63.60
224.40
6,645.40
7,921.40
5,180.40
Other Assets
13.40
-
-
-
-
Total Assets
77.00
224.40
6,645.40
7,921.40
5,180.40
ST Debt & Current Portion LT Debt
6,048.20
554.70
53.00
5.00
5.00
Accounts Payable
1,450.10
-
967.40
1,224.90
1,508.30
Other Current Liabilities
1,346.80
693.40
26,985.40
506.90
9.00
Total Current Liabilities
8,845.00
1,248.10
28,005.70
1,736.80
1,522.30
Total Liabilities
8,845.00
1,248.10
28,005.70
1,736.80
1,522.30
Common Equity (Total)
8,768.00
1,023.60
21,360.40
6,184.60
3,658.10
Total Shareholders' Equity
8,768.00
1,023.60
21,360.40
6,184.60
3,658.10
Total Equity
8,768.00
1,023.60
21,360.40
6,184.60
3,658.10
Liabilities & Shareholders' Equity
77.00
224.40
6,645.40
7,921.40
5,180.40

About TapImmune

View Profile
Address
5 West Forsyth Street
Jacksonville Florida 32202
United States
Employees -
Website http://www.tapimmune.com
Updated 09/14/2018
TapImmune, Inc. is an immuno-oncology company, which engages in the development of technologies for the treatment of cancer, including metastasis, and infectious diseases. It also involves in developing vaccines for breast, colorectal, ovarian, and non-small cell lung cancer. The company was founded in 1991 and is headquartered in Jacksonville, FL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.